Cocrystal Pharma (COCP)
Develops structure-designed antivirals for influenza, norovirus, and coronavirus infections.
Something off on this page? Send us feedback.
Develops small-molecule antiviral candidates through structure-based design, centered on CC-42344 for influenza and CDI-988 for norovirus and coronavirus infections. With no marketed products, it operates as a focused clinical-stage R&D organization dependent on trial, regulatory, and financing progress.
Uses structure-based drug design to develop small-molecule antivirals that inhibit conserved viral replication proteins. Its visible clinical programs are CC-42344 for influenza and CDI-988 for norovirus and coronavirus infections. The portfolio has no marketed products and represents a focused research-and-development activity rather than multiple operating businesses.
Managed from Bothell, Washington, the U.S.-based organization directs its work toward diseases with global incidence. Its scientific execution centers on studying three-dimensional viral enzyme structures and designing inhibitors for functionally important binding sites.
Progress depends on clinical safety and efficacy evidence, regulatory clearance, investigational-supply manufacture, and continued external capital. The concentrated pipeline also relies on patent and know-how protection, outside providers, and continued Nasdaq compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.2M · Total debt $1.3M · Total assets $4.6M · Shareholders' equity $1.0M
- Revenue
- $105.0K
- Operating income
- −$3.2M
- Net income
- −$3.2M
No dividends on record.
| Institutions25 holders · as of Mar 31, 2026 | 4.03% | 776.2K shares | |
| Insiders8 holders · as of Aug 7, 2026 | 36.46% | 7.02M shares | |
| Strategic holders1 holder · as of Aug 7, 2026 | 29.55% | 5.69M shares | |
| Otherremainder | 29.96% | 5.77M shares |
19.26M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (19.26M in the company's Sep 3, 2026 report, 13.79M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Opko Health, Inc.Strategic | 29.55% | 5.69M | 13Dfiled Aug 7, 2026 ↗ |
Phillip Md Et Al Frost1Insiderdirector, 10 percent owner | 14.46% | 2.78M | 13Dfiled Aug 7, 2026 ↗ |
Steven D. RubinInsiderdirector | 13.81% | 2.66M | Form 4filed Oct 11, 2024 ↗ |
Fred HassanInsiderdirector | 7.18% | 1.38M | Form 4filed Oct 30, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 1.25% | 239,971 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Phillip Md Et Al Frost's transaction reports restate only vehicles that traded; the 2026 ownership statement (2.78M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Phillip Md Et Al Frost | director, 10 percent owner: | +10,000 | $0.9816 |
| Aug 3, 2026 | Phillip Md Et Al Frost | director, 10 percent owner: | +75,000 | $0.9412 |
| Feb 24, 2026 | Phillip Md Et Al Frost | director, 10 percent owner: | +20,000 | $0.9976 |
| Feb 6, 2026 | Phillip Md Et Al Frost | director, 10 percent owner: | +50,000 | $0.9456 |
| Dec 31, 2025 | Phillip Md Et Al Frost | director, 10 percent owner: | +50,000 | $0.9455 |
- Pfizer
Paxlovid is the leading oral coronavirus antiviral benchmark.
- Gilead Sciences
Veklury is an approved coronavirus antiviral across care settings.
- Merck
Lagevrio and CD388 create coronavirus and influenza competition.
- Moderna
Respiratory and norovirus vaccines compete by reducing treatment demand.
- Vaxart
Oral pill norovirus vaccine program targets a prevention alternative.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cocrystal Pharma | $1.16 | +3.57% | $16.0M | — | — | 48.5 | — |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Moderna | $147.55 | −2.17% | $59.84B | — | — | 26.9 | +2.1% |
| Vaxart | $0.4951 | +0.73% | $118.7M | 3.3 | — | 0.5 | −31.6% |
| Median | 38.3 | 16.5 | 5.6 | +2.6% |